Streetbeat News

Products Services

GNLN

Greenlane Holdings, Inc. (NASDAQ:GNLN) is launching a new line of fentanyl, xylazine, and drink spike detection test strips under the Safety Strips brand. This move aligns with California's new law requiring clubs and bars to offer drug testing devices. The products will be available for order starting September 25th, with shipments beginning October 1st.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:37 pm

BDRX

Biodexa Pharmaceuticals has completed a $3 million final match payment to access the remaining $17 million from a CPRIT grant. This funding will support a Phase 3 study of eRapa in treating Familial Adenomatous Polyposis, marking a strategic milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:37 pm

FCUV

Focus Universal Inc. (NASDAQ:FCUV) announced a registered direct offering of 3.75 million shares at $0.32 each, raising approximately $1.2 million. The proceeds will support the development of a new software product platform under Lusher Inc.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:37 pm

CYTO

Altamira Therapeutics has expanded its license and distribution agreement with Nuance Pharma for the Bentrio nasal spray. The agreement now includes seven additional countries in East and South East Asia, with a combined population of over 630 million. Nuance Pharma has already launched Bentrio in Hong Kong and is seeking marketing authorization in Mainland China.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:34 pm

STIM

NeuroStar has announced software upgrades for its NeuroStar Advanced Therapy and TrakStar Patient Data Management Software, potentially enhancing their product offerings.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:33 pm

CLDX

Celldex Therapeutics announced that their Phase 2 study results for barzolvolimab in treating chronic spontaneous urticaria will be presented at the EADV Congress 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:33 pm

AEMD

Aethlon Medical has activated the Royal Adelaide Hospital to begin patient screening and enrollment for its Hemopurifier cancer trial. This trial focuses on patients with solid tumors not responding to anti-PD-1 antibodies.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:33 pm

KRNT

DO Apparel is expanding its digital production capabilities for custom sports jerseys by purchasing a second Kornit Atlas MAX POLY machine. This move enhances their ability to deliver on-demand, cost-effective sportswear for large sports organizations, marking a shift from traditional screen printing to digital production.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:32 pm

COYA

Coya Therapeutics has announced that its subcutaneously administered COYA 302 has shown a direct anti-inflammatory effect in the brain in a preclinical inflammatory mouse model of Parkinson's Disease. This development could have implications for future treatments of neuroinflammatory conditions.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:30 pm

TCMD

Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received PDAC approval for its Nimbl Lymphedema Platform, allowing it to be billed under HCPCS code E0651. This follows FDA clearance in June 2024, with commercial availability in the U.S. expected soon.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:30 pm